{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:07Z","timestamp":1786135987973,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Goals:<\/jats:title>\n                    <jats:p>Our aim was to perform a national survey of provider attitudes, practices, and knowledge regarding weight loss and MASLD medications in patients with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While weight loss is a cornerstone in the management of metabolic dysfunction-associated steatotic liver disease (MASLD), FDA-approved medications for weight loss remain underutilized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We conducted a survey before resmetirom approval of hepatology and gastroenterology providers practicing in 44 states. Surveys were sent to 747 providers with 304 complete responses (41%), of whom 260 (86%) work at a liver transplant center. While nearly all respondents (96%) believed that weight loss medications could benefit patients with MASLD, 77% have never\/rarely prescribed them due to low comfort (81%). Among weight loss medication prescribers, glucagon-like peptide-1 (GLP-1) receptor agonists were preferred (66%). In contrast, 63% had prescribed off-label medications for MASLD in the past 12 months, most commonly vitamin E (30%) and GLP-1 receptor agonists (25%). The top reported barriers to prescribing weight loss medications were lack of training\/unfamiliarity, cost\/insurance coverage, and side-effects, which may be explained by low formal obesity education and lack of knowledge (only 33% of FDA-approved medications for weight loss were correctly identified by &gt;50% of providers). Overall, there was reasonable provider-reported adherence to the 2023 AASLD practice guidance for MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This nationwide survey of hepatology and gastroenterology providers before resmetirom demonstrates that while off-label prescribing for MASLD was common, weight loss medication prescription rates remain very low due to low comfort possibly from insufficient education despite strong beliefs that they can benefit patients with MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcg.0000000000002147","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:00:27Z","timestamp":1750683627000},"page":"750-757","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Medications for Weight Loss and MASLD"],"prefix":"10.1097","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0009-8418","authenticated-orcid":false,"given":"Gene Y.","family":"Im","sequence":"first","affiliation":[{"name":"Center for Liver Disease and Transplantation, Columbia University Vagelos College of Physicians and Surgeons"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amon","family":"Asgharpour","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Aby","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Stine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Mellinger","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Henry Ford Health, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Luther","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Alcohol Liver Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhal","family":"Izzy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Haque","sequence":"additional","affiliation":[{"name":"Yale Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Lee","sequence":"additional","affiliation":[{"name":"Liver Program, Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Cotter","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney B.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta L.","family":"Jophlin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Hepatology and Nutrition, University of Louisville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Goel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rice","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Chandna","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Lizaola-Mayo","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona, Liver Transplantation Center, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena B.","family":"Bansal","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Division of Liver Diseases, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260807","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R2-20260807","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R3-20260807","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large US claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"R4-20260807","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","article-title":"Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort","volume":"20","author":"Malespin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/hep.30658","article-title":"Incorporating weight loss medications into hepatology practice for nonalcoholic steatohepatitis","volume":"70","author":"Do","year":"2019","journal-title":"Hepatology"},{"key":"R8-20260807","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.9486","article-title":"Progress in pharmacotherapy for obesity","volume":"326","author":"Yanovski","year":"2021","journal-title":"JAMA"},{"key":"R9-20260807","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20260807","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.jhepr.2021.100411","article-title":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","volume":"4","author":"Anstee","year":"2021","journal-title":"JHEP Rep"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"R12-20260807","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cgh.2019.07.042","article-title":"Provider attitudes and practice patterns for direct-acting antiviral therapy for patients with hepatocellular carcinoma","volume":"18","author":"Rich","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/diseases6040091","article-title":"When to initiate weight loss medications in the NAFLD population","volume":"6","author":"Yoo","year":"2018","journal-title":"Diseases"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"586","DOI":"10.21037\/hbsn-22-58","article-title":"Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease","volume":"11","author":"Zoncap\u00e8","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R17-20260807","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11695-020-04987-2","article-title":"Pharmacotherapy for obesity-trends using a population level national database","volume":"31","author":"Elangovan","year":"2021","journal-title":"Obes Surg"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/oby.21136","article-title":"Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010","volume":"23","author":"Xia","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/oby.2009.69","article-title":"How physician obesity specialists use drugs to treat obesity","volume":"17","author":"Hendricks","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"777131","DOI":"10.3389\/fcvm.2021.777131","article-title":"Statins in non-alcoholic steatohepatitis","volume":"8","author":"Torres-Pe\u00f1a","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R21-20260807","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"R22-20260807","doi-asserted-by":"crossref","first-page":"101816","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R23-20260807","first-page":"CD008623","article-title":"Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","author":"Eslami","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R24-20260807","first-page":"JCMC621","article-title":"E-mail survey response rates: a review","volume":"6","author":"Sheehan","year":"2001","journal-title":"J Comput-Mediat Commun"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCG.0000000000002147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:00:39Z","timestamp":1786132839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCG.0000000000002147"}},"subtitle":["A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom"],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000002147","relation":{},"ISSN":["1539-2031"],"issn-type":[{"value":"1539-2031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"2024-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}